Supernus Pharmaceuticals, Inc. (SUPN) 은(는) 상장 기업입니다 헬스케어 섹터의 Drug Manufacturers - Specialty & Generic 산업에서 운영. 본사 소재지는 Rockville, MD, 미국. 현재 CEO는 Jack A. Khattar.
SUPN 을(를) 보유 IPO 날짜 2012-05-01, 674 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $2.89B.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Rockville, Maryland, specializing in the development and commercialization of central nervous system (CNS) disease treatments. The company's commercial portfolio includes Trokendi XR and Oxtellar XR for epilepsy and migraine management, Qelbree for pediatric ADHD, and several Parkinson's disease treatments including APOKYN, XADAGO, GOCOVRI, and Osmolex ER, as well as MYOBLOC for cervical dystonia and sialorrhea. Beyond its marketed products, Supernus maintains a pipeline of investigational candidates at various clinical stages, including SPN-830 for Parkinson's disease, SPN-817 for severe epilepsy, and SPN-820 for treatment-resistant depression. The company distributes its products through pharmaceutical wholesalers, specialty pharmacies, and distributors across the United States.
